What amount sold does AI3 Bio, Inc. report in Form D filings?

The latest linked filings report $116M sold across 4 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was AI3 Bio, Inc.'s most recent SEC filing?

AI3 Bio, Inc.'s most recent Form D filing was on 2026-11-04.

How many investors does AI3 Bio, Inc. have?

The most recent Form D filing lists 7 investor(s).

What type of securities does AI3 Bio, Inc. offer?

AI3 Bio, Inc.'s SEC Form D filings indicate equity offerings.

AI3 Bio, Inc.

CIK: 0002019875·Biotechnology·WATERTOWN, MA·Corporation

Reported Sold

$116,035,146

Total Filings

Identified Offerings

Last Filed

Nov 4, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Nov 4, 2026Form D — New notice

Reported sold: $48,339,490 · Target: $48,339,490

Rule 506(b)·8 investors

Nov 4, 2026Form D — New notice

Reported sold: $0 · Target: Indefinite

Rule 506(b)·7 investors

Oct 20, 2025Form D — New notice

Reported sold: $16,754,446 · Target: $16,754,446

Rule 506(b)·4 investors

Aug 11, 2025Form D/A — Amendment

Reported sold: $58,510,656 · Target: $63,455,390

No verified predecessor available.

Rule 506(b)·14 investors

Apr 23, 2024Form D — New notice

Reported sold: $50,941,210 · Target: $50,941,210

Rule 506(b)·14 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

20%

Latest reported sold across 4 identified offerings

$116,035,146

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Nick Seaver

Related Person

Appears on 5 filings

Jonathan Kagan

Related Person

Appears on 5 filings

Alan Ezekowitz

Related Person

Appears on 5 filings

Andrew Bellinger

Related Person

Appears on 3 filings

Andrew Cornforth

Related Person

Appears on 2 filings

Steven Altschuler

Related Person

Appears on 2 filings

Steve Altschuler

Related Person

Appears on 2 filings

Richard Malley

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 4, 2026	New	$48,339,490	$48,339,490	8
Nov 4, 2026	New	Indefinite	$0	7
Oct 20, 2025	New	$16,754,446	$16,754,446	4
Aug 11, 2025	Amendment	$63,455,390	$58,510,656	14
Apr 23, 2024	New	$50,941,210	$50,941,210	14

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026